(1)BY-101 (2)BY-102 (3)BY-103
Model: (1)BY-101 (2)BY-102 (3)BY-103
Category: Pharmaceutical
Exhibitor: BOYEN THERAPEUTICS, INC.
Booth No: L222
Characteristic
BoYen has a platform that creates patentable new drug candidates. Currently, 3 candidates are under development. BY-101 is an USFDA designated orphan drug with a 7-year marketing exclusivity; the phase 2 candidate is intended for the treatment of acute myeloid leukemia (AML). BY-102 is a patented drug candidate for the treatment of multiple sclerosis and other immune related diseases. BY-103 is a patented drug candidate for oral combination treatment of AML. Its phase 1 trial begins this fall.
Products you may be interested in
Highest Rated Products